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Suppressors of cytokine signaling (SOCS) are a family of eight proteins that negatively 
regulate Janus kinase and signal transducers and activators of transcription signaling in 
cells that utilize this pathway to respond to extracellular stimuli. SOCS are best known for 
attenuating cytokine signaling in the immune system. However, they are also expressed 
in many other cell types, including pancreatic β-cells, where there is considerable interest 
in harnessing SOCS molecules to prevent cytokine-mediated apoptosis during diabetes 
and allogeneic transplantation. Apart from their potential as therapeutic targets, SOCS 
molecules play a central role for regulating important functions in β-cells, including 
growth, glucose sensing, and insulin secretion. This review will discuss SOCS proteins 
as central regulators for diverse cellular processes important for normal β-cell function as 
well as their protective anti-apoptotic effects during β-cell stress.
Keywords: suppressors of cytokine signaling, β-cells, SOCS expression, insulin signaling, inflammatory cytokines, 
diabetes, β-cell growth
iNTRODUCTiON
β-cells within the islets of Langerhans secrete the hormone insulin, not only in response to glucose 
but also in response to other nutrients, hormones, and neuronal stimuli (1). The primary role of 
β-cells is to maintain plasma glucose levels within tight physiological ranges for optimal functioning 
of the body’s cells. Normal physiology places high demands on β-cells compared to non-secretory 
cells, which may contribute to pathological conditions associated with pancreatic islet destruction 
and dysfunction, including types 1 and 2 diabetes. Type 1 diabetes develops from the autoimmune 
destruction of β-cells, while type 2 diabetes results from insulin resistance that ultimately causes 
β-cell exhaustion. Although the etiology of each disease is different, both disorders involve β-cell 
dysregulation through cytokine-induced inflammation (2, 3).
The capacity of β-cells to respond to their environment and dynamically adjusts blood glucose 
levels depend on multiple receptors and biological signaling pathways that interactively mediate glu-
cose sensing and insulin secretion. Many of these pathways initiate signal transduction by activating 
the Janus kinase and signal transducers and activators of transcription (JAK–STAT) pathway (4). It is 
now established that JAK–STAT signaling is inhibited by a family of intracellular proteins collectively 
known as suppressors of cytokine signaling (SOCS) that reduce the magnitude and/or duration of 
signals induced by diverse receptors (5–8). Although originally known for inhibiting cytokine signal-
ing in immune cells through a classical negative feedback loop, SOCS proteins emerged as important 
modulators of additional pathways, including those that control insulin secretion and β-cell develop-
ment and proliferation. Eight members of the SOCS family have been described, including SOCS-
1–7 and CIS. SOCS molecules have in common that they contain a central Src-homology 2 (SH2) 
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domain, a conserved COOH-terminal SOCS box, and a variable 
N-terminal domain (9, 10). Two SOCS molecules, SOCS-1 and 
SOCS-3, contain a kinase inhibitory region (KIR) (11, 12). SOCS 
proteins inactivate JAK–STAT signaling by binding directly to the 
tyrosine-phosphorylated residues on JAKs via the SH2 domain 
that blocks access of STATs to receptor-binding sites. They also 
suppress signaling by directly inhibiting JAK kinase activity and 
by targeting receptors and JAKs for degradation by the protea-
some [reviewed in Ref. (13, 14)]. Here, we focus on what is known 
about the expression of SOCS proteins in β-cells and how SOCS 
molecules regulate β-cell function under normal and pathophysi-
ological conditions.
SOCS eXPReSSiON iN β-CeLLS
In general, Socs genes are expressed at low or undetectable levels 
in resting cells but become rapidly induced after stimulation 
with cytokines or hormones. Their transcription is upregulated 
by the STAT and NFκB-transcription factors, and the resultant 
SOCS proteins generated subsequently suppresses the same 
pathway that stimulated their production. Table  1 describes 
what is currently known about the expression of different SOCS 
family members in β-cells. In primary human and mouse β-cells, 
SOCS-1, -2, and CIS are expressed at low baseline levels, although 
SOCS-3 message and protein are virtually undetectable in unma-
nipulated healthy islets. Interestingly, expression of SOCS-1, -2, 
and -3 proteins is upregulated in islet cells from human type 
1 diabetes (T1D) patients compared to healthy controls (15). 
Also, islets purified from NOD mice that develop spontaneous 
T1D express increased levels of SOCS during the progression of 
pancreatic insulitis, including CIS and SOCS-2 transcripts from 
7 weeks of age and SOCS-1 transcripts from 10 weeks of age (16). 
These findings suggest that β-cells synthesize SOCS proteins in 
response to the pro-inflammatory environment that accompanies 
β-cell autoimmunity.
Several studies have investigated which specific cytokines 
induce SOCS expression in β-cells. These have revealed that 
some cytokines induce the expression of several Socs genes, while 
others induce only one or a few. Chong et al. demonstrated that 
interferon γ (IFNγ) induces prolonged SOCS-1 mRNA expres-
sion (>48 h) in NIT-1 cells, a NOD mouse-derived insulinoma 
cell line, which peaks 4 h after cells are cultured with the cytokine. 
They also found that IFNα stimulates NIT-1 cells to transiently 
express SOCS-1 that peaks 2 h after stimulation and then rapidly 
decays (16). Primary mouse islets separately treated with IFNγ, 
but not IL-1β or TNFα, upregulated SOCS-1 expression. In the 
same study, SOCS-2 and CIS expression were rapidly induced 
in NIT-1 cells and mouse islets, incubated separately with IFNγ, 
IL-1β, or TNFα. However, IFNα did not increase CIS and SOCS-2 
transcripts above baseline levels (16).
Interleukin-1β rapidly stimulated SOCS-3 transcription in 
the RINm5F rat β-cell line that spiked 2 h after incubation (17, 
18). SOCS-3 mRNA is also induced in primary human β-cells 
exposed to IL-1β, although the effect on SOCS-3 expression was 
greater when IL-1β was combined with IFNγ and TNFα (19, 20) 
In rat islets, IL-1β stimulated a 20-fold increase in SOCS-3 mRNA 
after 4 h of culture that returned to baseline levels within 24 h 
(19, 21). IFNγ also upregulated SOCS-3 transcription; however, 
the increase in expression was transient compared to IL-1β and 
the effect disappeared within 24 h after stimulation. The combina-
tion of IL-1β and IFNγ additively increased SOCS-3 mRNA levels 
in rat islets. By contrast, Lv et al. found that combined IL-1β and 
IFNγ treatment actually downregulated SOCS-3 protein expres-
sion in the RIN rat β-cell line and in primary rat islets after 1 and 
24 h of incubation, respectively (22).
Suppressors of cytokine signaling proteins are also expressed 
in response to hormones that alter energy metabolism to accom-
modate different physiological conditions. Pregnancy induced 
high levels of CIS and SOCS-2 transcription in mice when β-cell 
proliferation was stimulated by lactogens (23, 24). SOCS-3 tran-
scription is also induced when rat and human β-cells are treated 
with leptin, a satiety hormone (19, 20, 25). Another study showed 
that resistin, an adipokine that contributes to insulin resistance, 
induces SOCS-3 protein expression in primary mouse β-cells 
(26). It is important to note that multiple post-transcriptional 
mechanisms are used to regulate the levels of some SOCS proteins 
(27). Therefore, measuring mRNA transcription alone may not 
adequately describe SOCS expression in β-cells.
eFFeCTS OF SOCS ON iNSULiN 
PRODUCTiON AND SiGNALiNG
Suppressors of cytokine signaling proteins appear to “fine-
tune” insulin synthesis and secretion by β-cells in response to 
a variety of external stimuli. Some of these are hormones that 
stimulate or suppress insulin production for regulating normal 
energy metabolism, while others are cytokines that alter insulin 
signaling during inflammatory conditions. Although changes in 
SOCS expression undeniably affects insulin signaling in β-cells, 
disagreements between the model systems used to investigate this 
phenomenon has made it difficult to firmly establish the natural 
contribution of SOCS to pancreatic islet function. Some of these 
discrepancies are highlighted below.
Suppressors of cytokine signaling regulation of GH-stimulated 
insulin secretion was explored by RØnn and colleagues (28) 
because it was known that GH stimulates insulin production by 
β-cells (29, 30) and because SOCS molecules inhibit GH signal-
ing in other tissues (31–33). It was found that SOCS-3 inhibits 
GH-induced insulin mRNA transcription in a RIN-5AH β-cell 
line that was transfected with an inducible SOCS-3 expression 
system. SOCS-3 overexpression abolished STAT3 and STAT5 
activation and DNA-binding ability. The JAK2–STAT5 pathway 
is the main signaling pathway triggered by GH in β-cells where 
STAT5 molecules are known to translocate to STAT5-specific 
elements of the insulin promoter (29, 34–36). Thus, the authors 
postulated that SOCS-3 blocks GH-induced insulin production 
by reducing the amount of activated STAT5 available for stimulat-
ing insulin expression. These conclusions contrast with a more 
recent study by the same authors, which found that female mice 
with β-cell-specific overexpression of SOCS-3 actually exhibit 
enhanced glucose tolerance compared to littermate controls, 
in spite of developing smaller islets (37). It was postulated 
that SOCS-3 mediates inhibition of several different signaling 
TABLe 1 | expression of SOCS family members in β-cells.
SOCS family 
members
β-cell source Stimulation conditions Product 
measured
expression Reference
SOCS-1 Human islet cells Baseline; 10 healthy subjects mRNA Constitutively expressed at low levels (15)
IFNγ + IL-1β + TNFα mRNA Markedly increased compared to baseline
Baseline; 10 healthy subjects Protein Detected at low levels
Baseline; 3 T1D patients Protein High compared to healthy controls
Mouse islet cells Baseline (NOD.SCID) mRNA Constitutively expressed at low levels (16)
IL-1β (NOD.SCID) mRNA None detected
TNFα (NOD.SCID) mRNA None detected
IFNγ (NOD.SCID) mRNA Peak at 4 h post incubation
Baseline (NOD) mRNA Detected by 70 days of age
NIT-1 mouse  
β-cell line
IL-1β mRNA Does not induce unless combined with IFNγ (16)
TNFα mRNA Does not induce unless combined with IFNγ
IFNα mRNA Peak at 2 h post incubation
IFNγ mRNA Peak at 4 h post incubation and remains elevated
IFNγ Protein Increased after 4 h and remains elevated beyond 24 h
SOCS-2 Human islet cells Baseline; 10 healthy subjects mRNA Constitutively expressed at low levels (15, 56)
IFNγ + IL-1β + TNFα mRNA Markedly increased compared to baseline 
Baseline; 10 healthy subjects Protein Detected at low levels
Baseline; 3 T1D patients Protein High compared to healthy controls
Mouse islet cells Baseline (NOD.SCID) mRNA Low (16, 57)
Baseline (C57BL/6J) Protein Very low
IL-1β (NOD.SCID) mRNA Peak at 4 h post incubation
TNFα (NOD.SCID) mRNA Peak at 1 h post incubation
IFNγ (NOD.SCID) mRNA Peak at 1 h post incubation
Baseline (NOD) mRNA Detected by 50 days of age
Pregnancy (C57BL/6J, CD-1) mRNA Increased by day 14.5 of pregnancy (24)
NIT-1 mouse  
β-cell line
IL-1β mRNA Peak at 1 h post incubation (16)
TNFα mRNA Peak at 1 h post incubation
IFNα mRNA Not changed compared to baseline
IFNγ mRNA Peak expression at 1 h post incubation
SOCS-3 Human islet cells Baseline; 10 healthy subjects mRNA Constitutively expressed at low levels (15)
IFNγ + IL-1β + TNFα mRNA Sixfold increase at 4–6 h post incubation, remains elevated 
beyond 24 h
IL-1 mRNA Fourfold increase at 4 h post incubation, decays to baseline 
levels within 24 h
(15, 19)
Baseline; 10 healthy subjects Protein Detected at low levels
Baseline; 3 T1D patients Protein High compared to healthy controls (15)
Leptin mRNA Strong induction after 12 h (20)
Rat islet cells Baseline mRNA Low (19, 21, 28)
IFNγ mRNA Not different compared to baseline (19)
IFNγ mRNA Markedly increased compared to baseline (21, 28)
IL-1β + IFNγ mRNA 20-fold increase at 4 h post incubation and decays to 
baseline levels within 24 h
(19)
IL-1β + IFNγ Protein Below baseline (22)
RIN rat β-cell line IL-1β mRNA 4.3-fold increase at 2 h post incubation (17, 18, 20)
IL-1β + IFNγ Protein Below baseline (22)
INS-1 rat cell line Leptin mRNA Increased by 30 min post incubation (20)
Mouse islet cells Leptin (ob/ob) mRNA Peak at 6 h post incubation (in vivo treatment) (20)
Resistin (ICR) Protein Increased expression by 12 h (26)
CIS Mouse islet cells Baseline (NOD.SCID) mRNA Constitutively expressed (16)
IL-1β (NOD.SCID) mRNA Increased within 1 h post incubation
TNFα (NOD.SCID) mRNA Increased within 1 h post incubation
IFNγ (NOD.SCID) mRNA Increased within 1 h post incubation
Baseline (NOD) mRNA Detected at day 50 days of age
Pregnancy (C57BL/6J, CD-1) mRNA Increased by day 14.5 of pregnancy (24)
NIT-1 mouse  
β-cell line
IL-1β mRNA Peak at 1 h post incubation (16)
TNFα mRNA Peak at 1 h post incubation
IFNα mRNA Not different compared to baseline
IFNγ mRNA Peak at 1 h post incubation
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pathways in β-cells besides GH, some of which could enhance 
glucose-stimulated insulin secretion.
Suppressors of cytokine signaling-3 is important for how 
leptin affects insulin production by β-cells. Leptin is a hormone 
synthesized by white adipose tissue that regulates body fat mass 
by controlling appetite and energy expenditure through effects 
on the hypothalamus [reviewed in Ref. (38)]. Findings that 
leptin-deficient ob/ob mice and leptin receptor-defective db/
db mice develop hyperinsulinelima before the onset of a type 
2 diabetes phenotype led to discoveries that leptin also inhibits 
preproinsulin gene expression by β-cells (39–41). SOCS-3 has 
been established as a mediator of central leptin resistance (25, 
42). Laubner et al. found that SOCS-3 is also important for leptin-
mediated repression of insulin production in β-cells, the purpose 
of which is probably to adjust glucose homeostasis to the amount 
of body fat (20). Using the rat insulinoma cell line INS-1, it was 
demonstrated that leptin signaling in β-cells stimulates leptin 
receptor associated JAK2 tyrosine kinase activity that phospho-
rylates STAT3 and STAT5b, which bind to the SOCS-3 promoter 
inducing transcription. SOCS-3 in turn inhibits JAK–STAT 
signaling that is required for insulin expression. Dysregulation 
of SOCS-3 signaling may contribute to the development of type 
2 diabetes in obese individuals whose β-cells become resistant to 
leptin signaling, leading to chronic insulin hypersecretion that 
eventually causes β-cell failure.
Suppressors of cytokine signaling molecules appear to protect 
against the impaired insulin secretion by β-cells exposed to pro-
inflammatory cytokines. Previous studies have shown that IFNγ 
reduces glucose-stimulated insulin secretion in β-cell lines as 
well as rodent and human islets (43–45). Cottet et al. assessed 
whether overexpressing SOCS-1 in the insulin-secreting cell 
line, βTc-Tet, could inhibit the IFNγ-driven JAK–STAT signal 
transduction pathway and prevent IFNγ-induced reductions 
in insulin gene expression and secretion (46). Constitutive 
SOCS-1 expression blocked phosphorylation and nuclear 
translocation of STAT-1 compared to non-transduced βTc-Tet 
cells, and IFNγ-induced reductions in insulin mRNA levels 
and glucose-stimulated insulin secretion were prevented. These 
findings differed from a later study that showed no effects of 
SOCS-1 overexpression on cytokine-induced inhibition of 
glucose-stimulated insulin secretion using primary islets from 
mice transgenically overexpressing SOCS-1 that were incubated 
with different concentrations of glucose and a mixture of IL-1β, 
TNFα, and IFNγ (47). Possible reasons for this discrepancy are 
that the studies used different sources of β-cells, IFNγ concentra-
tions, culture conditions, and the origin and expression levels of 
SOCS-1 were also different.
Apart from regulating insulin expression, SOCS molecules 
may play a role in the desensitization of β-cells to autocrine/par-
acrine insulin signaling that follows prolonged glucose exposure. 
The chronic hyperglycemia and inflammatory cytokines that 
accompany type 2 diabetes are known to cause β-cells to become 
resistant to insulin signaling (48–51), which is usually required 
for normal β-cell functioning and survival (52, 53). The involve-
ment of SOCS in this phenomenon has been investigated because 
SOCS molecules cause insulin resistance in other insulin-sensitive 
tissues that are exposed to inflammatory cytokines (54). A link 
between SOCS-1 and glucose-attenuated insulin signaling was 
demonstrated by Venieratos et  al. who showed that prolonged 
exposure of the β-cell line βTc-6 to high glucose concentrations 
inhibited insulin-induced tyrosine phosphorylation of the insulin 
receptor (IR), IR substrate-2 (IRS-2), as well as PI3-kinase acti-
vation (55). These impairments were associated with enhanced 
endogenous interleukin-1β (IL-1β) by βTC-6 cells that, in turn, 
stimulated expression of SOCS-1. SOCS-1 was critical for desen-
sitization of β-cells to insulin signaling because specific ablation 
of this molecule by small interfering RNA restored insulin signal-
ing suppressed by high glucose. Although these authors found 
no effect of high glucose on SOCS-3 expression, another study 
demonstrated that SOCS-3 had very similar effects to SOCS-1 
for inhibiting insulin signaling in RINm5F cells, a rat pancreatic 
β-cell line, after exposure to IL-1β (17).
The role of SOCS family members besides SOCS-1 and 
SOCS-3 for regulating insulin production and signaling in 
β-cells remains unclear. Conditional β-cells ablation of CIS 
showed no non-redundant functions for this gene (24). Another 
study investigated the importance of SOCS-2 and found no dif-
ference in glucose-induced insulin secretion in islets isolated 
from SOCS-2 knockout (KO) mice compared to wild-type 
controls (56). SOCS-2-KO mice were also normal for insulin 
and glucose tolerance. However, a separate report showed 
that transgenic mice constitutively expressing SOCS-2 in 
β-cells develop severe defects in glucose metabolism that were 
attributed to profoundly altered insulin secretion to various 
secretagogues, perturbed Ca flux in response to glucose, and 
impaired proinsulin maturation (57). While these results could 
indicate a role for SOCS-2 in β-cell function, it is possible that 
the defects observed were artifacts related to the transgenic 
overexpression of SOCS-2 protein off the insulin promoter, 
which has caused similar disruptions in a variety of pancreas-
specific gene manipulations (58, 59).
SOCS ReGULATiON OF CYTOKiNe 
SiGNALiNG AND β-CeLL APOPTOSiS
Suppressors of cytokine signaling proteins play a central 
role for regulating how β-cells respond to cytokines. Pro-
inflammatory cytokines, such as IFNγ, IL-1β, and TNFα, are 
secreted by lymphocytes and macrophages within pancreatic 
infiltrates during T1D development and after allogeneic islet 
transplantation and contribute to β-cell destruction by induc-
ing a variety of pro-apoptotic processes (60, 61). SOCS-1 and 
SOCS-3 buffer β-cells against these effects by downregulat-
ing pro-inflammatory cytokine-signaling pathways. Besides 
understanding the natural effects of SOCS proteins in β-cells, 
there exists considerable interest in enhancing expression of 
these molecules to mitigate cytokine effects during T1D and 
after islet transplantation. Most of what is known about how 
SOCS proteins modulate β-cell cytokine responses has been 
discovered by a small number of researchers. A summary of 
their findings is described below.
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Suppressors of Cytokine Signaling-1
In the early 2000s, studies were conducted to determine 
whether SOCS-1 was involved in protecting β-cells against 
the pro- apoptotic effects of IFNγ. These were motivated by 
reports showing that IFNγ induces SOCS-1 that negatively 
regulated JAK/STAT signaling in a wide variety of cell types 
(62, 63). Chong et  al. showed that SOCS-1 overexpression in 
NIT-1 cells inhibited IFNγ signaling, which blocked STAT-1 
activation and IFNγ-induced apoptosis (16). However, natural 
expression of SOCS-1 did not affect the kinetics and intensity 
of IFNγ-signaling in primary β-cells, suggesting that SOCS-1 
might not be involved in regulating inflammatory cytokines 
under physiological conditions. However, it was subsequently 
found that β-cells from SOCS-1-KO mice were more susceptible 
to cell death when exposed to IFNγ in combination with TNFα 
compared to islets from wild-type mice (64). TNFα does not 
activate the JAK–STAT pathway. Thus, increased TNFα + IFNγ-
induced cell death in SOCS-1 (KO) islets may have been the 
result of hypersensitivity to TNFα-stimulated iNOS expression 
and nitric oxide (NO) production via dysregulation of the p38 
mitogen-activated protein kinase pathway. TNFα alone did not 
induce iNOS expression or cell death, indicating that the path-
ways stimulated by IFNγ are still necessary for iNOS induction 
in SOCS-1-KO β-cells. Similar results were obtained by Cottet 
et al. who showed that SOCS-1 overexpression prevents iNOS 
expression and apoptosis in βTc-Tet cells exposed to IFNγ in 
combination with TNFα and IL-1β (46).
More recent studies have employed SOCS-1 transgenic mice 
to examine how SOCS-1 overexpression affects β-cell resist-
ance against spontaneous T1D and allogeneic transplantation. 
Flodström-Tullberg et  al. found that spontaneous T1D was 
reduced in SOCS-1 transgenic NOD mice and that protection 
was associated with cytokine-induced STAT-1 phosphorylation 
within β-cells (65). Chong et al. obtained similar results showing 
that rat insulin promoter-driven SOCS-1 expression in β-cells 
prevents progression to diabetes in NOD mice and CD8+ TCR 
transgenic NOD.NY8.3 mice (66). Another study demonstrated 
that SOCS-1 transgenic mice are protected from virally induced 
CD8+ T cell-mediated T1D (67). In transplantation studies, islets 
from C57BL6 (B6) SOCS-1 transgenic mice survived longer 
than wild-type islets when engrafted into allogeneic BALB/c 
recipient mice (68). The same SOCS-1 transgenic islets did not 
survive better than controls when transplanted into clinically 
diabetic NOD mice, probably because of already high circulating 
levels of autoreactive T cells. Another report found that SOCS-1 
overexpression induced by an adenovirus system increased the 
survival of rat islets transplanted into allogeneic recipients with 
streptozotocin-induced diabetes (69).
Follow-up studies have identified several mechanisms 
through which SOCS-1 overexpression may improve β-cell 
survival in diabetes and islet transplantation models. Chong 
et al. showed that SOCS-1 inhibits IFNγ and TNFα-induced Fas 
and IL-15 expression by β-cells (66). In this way, SOCS-1 may 
prevent CD8+ T cells from killing β-cells through Fas–Fas ligand 
interactions and reduce IL-15-mediated homing and activation 
of diabetogenic T cells within the pancreas. Another group found 
that SOCS-1 transgenic islets express less of the IFNγ inducible 
chemokine Cxcl10 that is usually produced by islets during 
diabetes development and may be involved in recruitment of 
autoreactive T cells to the inflamed pancreas (70). Using islets 
from SOCS-1 transgenic mice on the B6 background, Zaitseva 
et al. demonstrated that SOCS-1 may block cytokine-mediated 
islet apoptosis by decreasing IFNγ, TNFα, IL-1β-induced 
caspase-3, -8, and -9 expression in β-cells (47). Usually, cas-
pase-3 activation, which can be initiated by caspases 8 and 9, is 
essential for the induction of apoptosis in β-cells (71, 72). Unlike 
previous reports, these authors found no evidence that SOCS-1 
prevents cytokine-mediated NO production and suggested that 
changes in NO production might not contribute to the protec-
tive effect of SOCS-1 overexpression in β-cells. In a separate 
report, Solomon et  al. showed that transgenic expression of 
SOCS-1 rendered islets resistant to IFNγ and TNFα-induced 
cell death and that resistance was correlated with a significant 
inhibition of the transcription factor interferon regulatory 
 factor-1 (IRF-1) (73). They proposed a model in which SOCS-1 
prevents cytokines from inducing IRF-1 that normally inhibits 
anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, by blocking 
the cytoprotective NFκB pathway (74–76). Several studies have 
found that SOCS-1 reduces β-cell expression of class I MHC 
molecules following exposure to pro-inflammatory cytokines 
(16, 66, 67, 73). IFNγ produced during allograft rejection and 
T1D development is known to upregulate class I MHC antigen 
on β-cells, which makes them more vulnerable to lysis by CD8+ T 
cells. SOCS-1 overexpression was demonstrated to reduce class 
I MHC expression by pancreatic islets incubated with IFNγ and 
TNFα and after LCMV infection (67). One report showed that 
physiological levels of SOCS-1 protein are sufficient to reduce 
class I MHC expression following cytokine exposure, because 
SOCS-1-deficient β-cells were more sensitive to TNFα-induced 
class I MHC expression compared to wild-type islets (64).
Suppressors of Cytokine Signaling-3
Different research groups using similar model systems pub-
lished reports characterizing SOCS-1 and SOCS-3 regulation 
of β-cell cytokine signaling, concurrently. An early study 
by Karlsen et  al. used INS-1 cells with doxycycline (DOX)-
inducible SOCS-3 expression to show that the apoptotic effects 
of IL-1β and IFNγ were, respectively, fully and partially blocked 
by SOCS-3 overexpression at moderate and high concentrations 
of both cytokines (21). The protective effects of SOCS-3 over-
expression were correlated with decreased IL-1β-induced iNOS 
promoter activity and NO production. In primary islet cells 
from rats and humans, SOCS-3 mRNA expression was induced 
by exposure to IL-1β alone and in combination with IFNγ and 
TNFα, indicating that SOCS-3 might contribute to the natural 
resistance of islets against the toxic effects of pro-inflammatory 
cytokines (19, 21).
A number of mechanisms have been identified, in addition 
to reduced NO production, through which SOCS-3 overex-
pression may protect islets from cytokine-mediated apoptosis. 
By comparing global gene expression following IL-1β exposure of 
INS-1 cells with and without DOX-induced SOCS-3 expression, 
6Ye and Driver SOCS Regulation of β-Cells
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it was found that multiple IL-1β-induced NFκB-dependent early 
apoptotic and immune genes were inhibited, including ICAM, 
complement C3, Mob-1, MIP-1, CX3C, NFκB–p105, IRF-1, and 
fibrinogen-γ (77). In a separate study, DOX-inducible SOCS-3 
INS-1 cells and primary rat islets transduced with a SOCS-3-
encoding adenovirus showed that IL-1β-induced expression of 
Fas and the chemokines Mcp-1, Mip-2, and St-38, which depend 
on the NFκB pathway, become inhibited by SOCS-3 overexpres-
sion (78). Collectively, these results suggest that by blocking NFκB 
activity, SOCS-3 may protect β-cells from attracting, engaging, 
and activating autoreactive T cells.
Suppressors of cytokine signaling-3 overexpression partially 
protects β-cells from immune responses that develop after 
allogeneic transplantation. RØnn et  al. showed that islets from 
B6 mice with β-cell-specific SOCS-3 expression survived longer 
compared to wild-type islets when transplanted into BALB/c 
mice (19). However, the same transgenic islets did not survive 
better than wild-type islets when transplanted into spontaneously 
diabetic NOD mice. Outcomes of these transplantation studies 
are remarkably similar to experiments using SOCS-1 transgenic 
islets (68, 69) and demonstrate that SOCS-3 expression can 
also protect islets against allogeneic MHC responses but can-
not circumvent the autoimmune responses that develop in the 
NOD mouse. It is not yet known whether SOCS-3 transgenic 
expression impacts spontaneous diabetes. However, one report 
examined whether β-cell-specific SOCS-3 expression could 
protect B6 mice from multiple low-dose streptozotocin-induced 
diabetes development (79). Surprisingly, SOCS-3 transgenic mice 
tended to develop accelerated disease compared to wild-type 
controls. To explain their findings, the authors proposed that 
increased SOCS-3 expression might, under some conditions, 
lead to a failed upregulation of protective pathways that would 
normally become activated after β-cell exposure to inflammatory 
cytokines. In support of this hypothesis, the investigators showed 
that SOCS-3 overexpression in mouse and rat islets reduced 
IL-1β-induced expression of IL-1Rα, a glycolipid that antagonizes 
IL-1β-induced β-cell damage (80). Another explanation for the 
increased sensitivity of SOCS-3 transgenic mice to MLDSTZ-
induced diabetes is that SOCS-3 overexpression could obstruct 
normal β-cell functioning, for instance, by interfering with JAK/
STAT-dependent insulin signaling.
Although much emphasis has been placed on understand-
ing SOCS-3 modulation of IL-1β and IFNγ signaling in β-cells, 
Bruun et al. demonstrated that SOCS-3 expression also inhibits 
TNFα signaling (81). They further showed that TNFα tran-
siently induces the expression of SOCS-3 mRNA in primary rat 
β-cells, through stimulating NFκB and MAP kinases. Apoptosis 
mediated by TNFα alone or in combination with IL-1β was sup-
pressed by overexpression of SOCS-3 in INS-1 cells by repress-
ing TNFα-induced IκB degradation, NFκB DNA binding, and 
NFκB-transcription of MnSOD, a classical example of an NFκB 
responsive gene.
Overexpression studies have established that SOCS-3 is 
capable of regulating signaling induced by at least three major 
cytokines involved in the pathogenesis of T1D. Consequently, 
SOCS-3 represents a promising target for therapeutic interven-
tions to protect β-cell mass. However, unlike SOCS-1, there 
is little known about how SOCS-3 contributes to the natural 
resistance of β-cells against cytokine-mediated toxicity, in part, 
because data are lacking about SOCS-3-deficient β-cells. SOCS-2 
is also expressed in β-cells, but the role of this SOCS member 
on β-cell apoptosis has yet to be firmly established. Puff et  al. 
reported that IL-1β-mediated cell death in vitro was unchanged 
after siRNA mediated SOCS-2 knockdown in INS-1E cells. Also, 
destruction of β-cells after MLDSTZ injections was not altered in 
SOCS-2-KO mice (56). In contrast, Alkharusi et al. showed that 
6-month-old, but not 2-month-old, SOCS-2-KO mice were less 
sensitive to the effects of MLDSTZ treatment (82).
SOCS PROTeiNS MODULATe β-CeLL 
GROwTH AND RePLiCATiON
Growth hormone and prolactin (PRL) are hormones that stimu-
late β-cell replication through JAK–STAT-signaling receptors 
that are subject to suppression by SOCS proteins (83–88). Both 
GH and PRL stimulate β-cell growth and proliferation in  vitro 
(84, 89, 90). Furthermore, mice deficient for PRL receptor 
(PRLR) develop smaller β-cells and reduced pancreatic insulin 
content compared to wild-type controls (91). β-cell-specific GH 
receptor knockout (GHRKO) mice develop normal β-cell mass 
when raised on a standard chow diet (30). However, they exhibit 
a dramatic defect in β-cell hyperplasia when fed a high-fat diet 
(HFD), indicating that GH may be dispensable for normal β-cell 
development but required for β-cell compensatory growth in 
response to HFD challenge.
Pancreatic islets modulate expression of receptors for GH and 
PRL during periods of β-cell expansion, such as during develop-
ment, pregnancy, and lactation (87, 88, 92). It has been reported 
that SOCS proteins inhibit GH- and PRL-mediated signal trans-
duction and proliferation in multiple tissue types (31, 33, 93), 
which prompted studies to investigate whether SOCS molecules 
also suppress GH- and PRL-mediated growth in β-cells. RØnn 
et al. investigated the role of SOCS signaling in the β-cells lines 
RIN-5AH and INS-1 with inducible SOCS-3 expression (28). 
In a dose-dependent way, SOCS-3 inhibited GH-induced DNA 
binding of both STAT3 and STAT5 in RIN-5AH cells stably trans-
fected with a ponasterone-inducible SOCS-3 expression system. 
5-bromodeoxyuridine (BrdU) incorporation was used to show 
that SOCS-3 inhibits GH-induced proliferation of INS-1 cells 
in a dose-dependent manner with DOX-inducible expression of 
SOCS-3. Lindberg et al. examined the in vivo effects of specific 
transgenic overexpression of SOCS-3 in β-cells (37). In spite of 
large variation in SOCS-3 transgene expression, β-cell volume of 
transgenic mice was reduced by approximately 30% compared 
with β-cell volume in wild-type female mice. There was no dif-
ference in β-cell volume between male and female mice in either 
group or between male transgenic mice and male wild-type lit-
termates. This may have been because β-cell volume in wild-type 
female mice is usually relatively large compared to male mice, 
and, therefore, SOCS-3 overexpression may have had a more pro-
nounced effect on female than on male mice. SOCS-3 overexpres-
sion had no effect on the amount of proliferating β-cells, probably 
because inhibition of GH and/or PRL happened at an earlier stage 
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of development than when the mice were analyzed (2 months of 
age) (88). Transduction of primary neonatal rat islet cultures with 
recombinant adenoviruses expressing various SOCS proteins, 
followed by stimulation with GH, demonstrated that SOCS-3 
inhibits islet proliferation by GH (37). The effect appeared to be 
specific for SOCS-3, as SOCS-1, SOCS-2, or CIS expression did 
not affect GH-induced β-cell proliferation. Additional studies 
using SOCS-2-deficient (56) and SOCS-2 overexpressing mice 
(57) appear to rule out that SOCS-2 is involved in β-cell hyper-
trophy or replication.
Hormones besides GH and PRL induce β-cell growth. Some 
of these, such as placental lactogen (83, 87, 94) and glucagon-like 
peptide-1 (95), signal independently of the JAK/STAT pathway 
and are not subject to inhibition by SOCS molecules. SOCS 
proteins may regulate IR signaling that employs the JAK/STAT 
pathway and which appears to be important for maintaining adult 
β-cell mass (96) and inducing compensatory β-cell proliferation 
during HFD challenge (97). This question remains to be answered 
by future studies.
CONCLUSiON
The discovery that SOCS proteins are expressed in β-cells and 
interactively regulate a diverse range of signaling pathways has 
greatly advanced our understanding about how β-cell growth, 
function, and survival are controlled. They also provide insight 
about how β-cells manage to simultaneously regulate often 
contradictory signaling pathways for different families of recep-
tors, i.e., IR, GH/PRL receptors, leptin receptors, and cytokine 
receptors. Figure 1 describes some of these pathways. Although 
FiGURe 1 | Summary of cellular processes involved in β-cell function, survival, and replication that are reportedly regulated by SOCS molecules.
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